Abstract
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lancet |
Vol/bind | 356 |
Udgave nummer | 9247 |
Sider (fra-til) | 2052-8 |
Antal sider | 6 |
ISSN | 0140-6736 |
Status | Udgivet - 2000 |
Bibliografisk note
Keywords: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Phenethylamines; Sulfonamides; Ventricular Dysfunction, LeftCitationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. / Køber, L; Bloch Thomsen, P E; Møller, M; Torp-Pedersen, C; Carlsen, J; Sandøe, E; Egstrup, K; Agner, E; Videbaek, J; Marchant, B; Camm, A J; Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.
I: Lancet, Bind 356, Nr. 9247, 2000, s. 2052-8.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial
AU - Køber, L
AU - Bloch Thomsen, P E
AU - Møller, M
AU - Torp-Pedersen, C
AU - Carlsen, J
AU - Sandøe, E
AU - Egstrup, K
AU - Agner, E
AU - Videbaek, J
AU - Marchant, B
AU - Camm, A J
AU - Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group
N1 - Keywords: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Phenethylamines; Sulfonamides; Ventricular Dysfunction, Left
PY - 2000
Y1 - 2000
N2 - BACKGROUND: Arrhythmias cause much morbidity and mortality after myocardial infarction, but in previous trials, antiarrhythmic drug therapy has not been convincingly effective. Dofetilide, a new class III agent, was investigated for effects on all-cause mortality and morbidity in patients with left-ventricular dysfunction after myocardial infarction. METHODS: In 37 Danish coronary-care units, 1510 patients with severe left-ventricular dysfunction (wall motion index < or = 1.2, corresponding to ejection fraction < or = 0.35) were enrolled in a randomised, double-blind study comparing dofetilide (n=749) with placebo (n=761). The primary endpoint was all-cause mortality. Secondary endpoints included cardiac and arrhythmic mortality and total arrhythmic deaths. Analyses were by intention to treat. FINDINGS: No significant differences were found between the dofetilide and placebo groups in all-cause mortality (230 [31%] vs 243 [32%]), cardiac mortality (191 [26%] vs 212 [28%]), or total arrhythmic deaths (129 [17%] vs 140 [18%]). Atrial fibrillation or flutter was present in 8% of the patients at study entry. In these patients, dofetilide was significantly better than placebo at restoring sinus rhythm (25 of 59 vs seven of 56; p=0.002). There were seven cases of torsade de pointes ventricular tachycardia, all in the dofetilide group. INTERPRETATION: In patients with severe left-ventricular dysfunction and recent myocardial infarction, treatment with dofetilide did not affect all-cause mortality, cardiac mortality, or total arrhythmic deaths. Dofetilide was effective in treating atrial fibrillation or flutter in this population.
AB - BACKGROUND: Arrhythmias cause much morbidity and mortality after myocardial infarction, but in previous trials, antiarrhythmic drug therapy has not been convincingly effective. Dofetilide, a new class III agent, was investigated for effects on all-cause mortality and morbidity in patients with left-ventricular dysfunction after myocardial infarction. METHODS: In 37 Danish coronary-care units, 1510 patients with severe left-ventricular dysfunction (wall motion index < or = 1.2, corresponding to ejection fraction < or = 0.35) were enrolled in a randomised, double-blind study comparing dofetilide (n=749) with placebo (n=761). The primary endpoint was all-cause mortality. Secondary endpoints included cardiac and arrhythmic mortality and total arrhythmic deaths. Analyses were by intention to treat. FINDINGS: No significant differences were found between the dofetilide and placebo groups in all-cause mortality (230 [31%] vs 243 [32%]), cardiac mortality (191 [26%] vs 212 [28%]), or total arrhythmic deaths (129 [17%] vs 140 [18%]). Atrial fibrillation or flutter was present in 8% of the patients at study entry. In these patients, dofetilide was significantly better than placebo at restoring sinus rhythm (25 of 59 vs seven of 56; p=0.002). There were seven cases of torsade de pointes ventricular tachycardia, all in the dofetilide group. INTERPRETATION: In patients with severe left-ventricular dysfunction and recent myocardial infarction, treatment with dofetilide did not affect all-cause mortality, cardiac mortality, or total arrhythmic deaths. Dofetilide was effective in treating atrial fibrillation or flutter in this population.
M3 - Journal article
C2 - 11145491
VL - 356
SP - 2052
EP - 2058
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9247
ER -